Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

407.83 +17.81 (+4.57%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

69 70 Next >

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress ↗

March 20, 2025

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Via Benzinga

Amgen's Options: A Look at What the Big Money is Thinking ↗

March 12, 2025

Via Benzinga

Assessing Amgen: Insights From 9 Financial Analysts ↗

March 05, 2025

Via Benzinga

Behind the Scenes of Amgen's Latest Options Trends ↗

March 04, 2025

Via Benzinga

Looking Into Amgen's Recent Short Interest ↗

February 19, 2025

Via Benzinga

Behind the Scenes of Amgen's Latest Options Trends ↗

March 20, 2025

Via Benzinga

Prediction: These 2 Stocks Will Outperform the Market Through 2030 ↗

March 18, 2025

Via The Motley Fool

Motley Fool Market Cap Showdown: Bill Barker vs. Emily Flippen ↗

March 14, 2025

Via The Motley Fool

Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year ↗

March 13, 2025

Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with two doses a year.

Via Benzinga

Amgen Unusual Options Activity For February 12 ↗

February 12, 2025

Via Benzinga

Is Eli Lilly Stock a Buy? ↗

March 11, 2025

Via The Motley Fool

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗

March 10, 2025

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Via Benzinga

3 Magnificent Growth Stocks to Buy in March ↗

March 08, 2025

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

March 07, 2025

Via The Motley Fool

2 Reasons to Watch AMGN and 1 to Stay Cautious

March 06, 2025

Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.

Via StockStory

Topics Stocks

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗

March 06, 2025

Via Benzinga

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 05, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform ↗

February 28, 2025

Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.

Via Benzinga

Topics ETFs Stocks

This Could Be the Best GLP-1 Stock to Buy in 2025 ↗

February 28, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys? ↗

February 25, 2025

Via The Motley Fool

Topics Stocks

Synchronicity: Denying The Unexplainable ↗

February 24, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Via Talk Markets

Topics Stocks / Equities

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 11, 2025

Via Benzinga

Gilead Sciences (GILD) Q4 Earnings: What To Expect

February 10, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect.

Via StockStory

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

3 Fabulous Dividend Stocks to Buy in February ↗

February 09, 2025

Via The Motley Fool

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.